TY - JOUR A1 - Üceyler, Nurcan A1 - Häuser, Winfried A1 - Sommer, Claudia T1 - Systematic review with meta-analysis: Cytokines in fibromyalgia syndrome N2 - Background: To perform a systematic review and meta-analysis on cytokine levels in patients with fibromyalgia syndrome (FMS). Methods: Through December 2010 we systematically reviewed the databases PubMed, MEDLINE, and PsycINFO and screened the reference lists of 22 review articles for suitable original articles. Original articles investigating cytokines in patients with FMS were included. Data were extracted by two independent authors. Differences of the cytokine levels of FMS patients and controls were summarized by standardized mean differences (SMD) using a random effects model. Study quality was assessed applying methodological scores: modified Center of Evidence Based Medicine, Newcastle-Ottawa-Scale, and Würzburg Methodological Quality Score. Results: Twenty-five articles were included investigating 1255 FMS patients and 800 healthy controls. Data of 13/25 studies entered meta-analysis. The overall methodological quality of studies was low. The results of the majority of studies were not comparable because methods, investigated material, and investigated target cytokines differed. Systematic review of the selected 25 articles revealed that FMS patients had higher serum levels of interleukin (IL)-1 receptor antagonist, IL-6, and IL-8, and higher plasma levels of IL-8. Meta-analysis of eligible studies showed that FMS patients had higher plasma IL-6 levels compared to controls (SMD = -0.34 [-0.64, -0.03] 95% CI; p = 0.03). The majority of investigated cytokines were not different between patients and controls. Conclusions: The pathophysiological role of cytokines in FMS is still unclear. Studies of higher quality and with higher numbers of subjects are needed. KW - Fibromyalgie Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-69189 ER - TY - THES A1 - Üceyler, Nurcan T1 - Charakterisierung genomischer Polymorphismen und somatischer Mutationen, sowie der Expression der gastrointestinalen Glutathionperoxidase im Rahmen der kolorektalen Karzinogenese T1 - Characterisation of genomic polymorphisms and somatic mutations and the expression of the gastrointestinal glutathionperoxidase during colorectal carcinogensis N2 - Das kolorektale Karzinom ist in der westlichen Welt die zweithäufigste Todesursache bei Männer und Frauen. Wichtige Pathomechanismen der kolorektalen Karzinome konnten in den letzten Jahren aufgedeckt werden. Die Anhäufung von genetischen Alterationen spielen sowohl bei sporadischen, als auch bei den hereditären Formen eine wichtige Rolle. Zwei molekulargenetische Hauptwege sind bei der kolorektalen Karzinogenese identifiziert worden: erstens der Tumorsuppressor-Pathway, bei dem es zu Alterationen in Tumorsuppresor- und Onkogenen kommt und zweitens der Mutatior-Pathway, der auf genetischen Alterationen in DNA-mismatch-Reparatur-Genen beruht, die zu einer genetischen Instabilität führen mit einer hohen Mutationsrate in repetitiven DNA-Sequenzen (sog. Mikrosatelliten). Es konnte gezeigt werden, dass oxidativer Stress, der durch die Bildung von H2O2 und anderen reaktiven Sauerstoffspezies (ROS) hervorgerufen wird, zur Entstehung von zellulären und DNA-Schäden wie z.B. oxidative Basenschäden, die ihrerseits u.a. die Entstehung von fixen Punktmutationen, Fragmentation der Desoxiribose und DNA-Strangbrüche initiieren, führen kann. Diese Veränderungen und auch die Mismatch-Reparatur-Defizienz begünstigen die Tumorprogression im Kolon. Es wird geschätzt, dass durch ROS täglich ca.20 000 hits pro Zelle verursacht werden. Es existieren sowohl extrazelluläre, als auch zelluläre antioxidative Abwhrsysteme, die Biomoleküle wie u.a. die DNA vor dem oxidativen Stress schützen. Unter diesen protektiven Enzymen gibt es neben der Superoxidismutase und der Katalase auch zahlreiche Selenoproteine, die Selenocystein in ihrem aktiven Zentrum tragen. Zu diesen Enzymen, die antioxidative Funktionen wahrnehmen gehören u.a. die Glutathionperoxidase, die Thioredoxinreduktase und das Selenoprotein P. Die Glutathionperoxidase-Familie besteht aus der cytosolischen Glutathioperoxidase (cGPx), der plasmatischen Glutathionperoxidase (pGPx), der gastrointestinalen Glutathionperoxidase (GI-GPx) und der Phospholipid-Hydroperoxid-Glutathionperoxidase (PH-GPx). Diese Enzymfamilie ist an der Reduktion von Hydroperoxiden beteiligt, wobei sie Glutathion als Cofaktor benutzt. Die Thioredoxinreduktase-Familie (TrxR-alpha und Trxr-beta) regeneriert oxidiertes Thioresoxin, das in die DNA-Synthese involviert ist und auch in zelluläre Redox-Regulationssysteme eingreift und Transkriptionsfaktoren beeinflusst. Das Selenoprotein P, das bis zu 10 Seleocysteinreste pro Molekül enthält, baut Peroxinitrit ab, das seinerseits ein starkes Agens bei der Nitrosylation von Biomolekülen ist. Zusätzlich reduziert Selenoprotein P auch Phospholipid-Hydroperoxide, wenn auch weniger effektiv als PH-GPx. Es konnte in Vorarbeiten gezeigt werden, dass Selenoproteine im Gastrointestinaltrakt eine differentielle Expression aufweisen. Kürzlich konnte in unserer Arbeitsgruppe die inverse mRNA-Expression selnocysteinhaltigen Proteine GI-GPx und Selenoprotein P in kolorektalen Adenomen im Vergleich zur Normalmukosa charakterisiert werden. Dabei zeigte sich eine dramatische Abnahme der Selenoprotein P-Expression, während die Expression der GI-GPx signifikant erhöht war. Im Rahmen der vorliegenden Arbeit untersuchten wir die Expression der GI-GPx in kolorektalen Karzinomen und Kolonkarzinom-Zelllinien, um auf Ebene der Selenoprotein-kodierenden Gene nach Alterationen zu suchen, die die veränderte Expression mit verursachen könnten. N2 - Colorectal cancer is the seceond most cancer in both men and women in the western world. Important mechanisms of the pathogenesis of colorectal cancers have been identified during the last years. Accumulation of genetic alterations plays an imprtant role in the carcinogenesis of both sporadic and inherited colorectal cancers. Two major molecular pathways have been characterised in colorectal carcinogenesis, first, the tumor suppressor pathway, with the hallmark of alterations in tumor suppressor genes (p53, APC, DCC) and oncogenes (K-ras), and second, the mutator pathway, based on genetic alterations in DNA mismatch repair genes, which lead to genetic instability with high mutation rate in repetitive DNA sequences (microsatellites). Oxidative stress caused by formation of H2O2 and other reactive oxygen species (ROS) was shown to contribute to cellular and DNA damage e.g. oxidative base damage leading to fixed point mutations, fragmentation of deoxyribose as well as DNA strand breaks, thereby promoting tumor progression in the colon as well as mismatch repair deficiency. It has been estimated, that the number of ROS induced hits accounts for 20 000 hits per cell per day. Both extracellular and cellular antioxidative defense systems have evolved which protect biomolecules including DNA from oxidative stress events. Among these protecting enzymes such as superoxide dismutase and catalase, various selenocysteine containing proteins (selenoproteins) with antioxidative functions like the glutathione peroxidases, the thioredoxin reductases and selenoprotein P have been identified. The glutathione peroxidase family consists of the cytosolic glutathione peroxidase (cGPx), plasma glutathione peroxidase (pGPx), gastrointestinal glutathione peroxidase (giGPx) and the phospholipid hydroperoxide glutathione peroxidase (phGPx) and is involved in reduction of hydroperoxides using glutathione as a cofactor. The thioredoxin reductase family (TrxRalpha and TrxRbeta) regenerates oxidized thioredoxin, which is involved in DNA synthesis as well as cellular redox regulation of enzymes and transcription factors. Selenoprotein P (SePP), containing up to 10 seleocysteine residues per molecule is assumed to quench peoxnitrite, a powerful agent in nitrosylation of biomolecules. In addition, SePP was suggested to reduce phospholipid hydroperoxides although less efficiently than phGPx. Selenoproteins have been shown to be differentially expressed along the gastrointestinal tract. Recently, we identified an inverse mRNA expression of the selenocysteine-containing proteins giGPx and SePP in colorectal adenomatous polyps comparad to adjacent normal mucosa. In particular, SePP expression was dramatically reduced in colon adenomas, whereas giGPx expression was markedly increased. Here, we investigated the expression of the selenoprotein giGPx in colorectal cancers and colorectal cancer cell lines and examined whether alterations of genes encoding selenoproteins contributes to the altered expression of selenoproteins in colorectal cancer. KW - kolorektale Karzinogenese KW - Antioxidantien KW - Selenoproteine KW - Glutathionperoxidase KW - Mikrosatelliteninstabilität KW - colorectal carcinogensis KW - antioxidants KW - selenoproteins KW - glutathionperoxidase KW - microsatellit-instability Y1 - 2003 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-5815 ER - TY - JOUR A1 - Politei, Juan M. A1 - Bouhassira, Didier A1 - Germain, Dominique P. A1 - Goizet, Cyril A1 - Guerrero-Sola, Antonio A1 - Hilz, Max J. A1 - Hutton, Elspeth J. A1 - Karaa, Amel A1 - Liuori, Rocco A1 - Üceyler, Nurcan A1 - Zeltzer, Lonnie K. A1 - Burlina, Alessandro T1 - Pain in fabry disease: practical recommendations for diagnosis and treatment JF - CNS Neuroscience & Therapeutics N2 - Aims: Patients with Fabry disease (FD) characteristically develop peripheral neuropathy at an early age, with pain being a crucial symptom of underlying pathology. However, the diagnosis of pain is challenging due to the heterogeneous and nonspecific symptoms. Practical guidance on the diagnosis and management of pain in FD is needed. Methods: In 2014, experts met to discuss recent advances on this topic and update clinical guidance. Results: Emerging disease-specific tools, including FabryScan, Fabry-specific Pediatric Health and Pain Questionnaire, and Wurzburg Fabry Pain Questionnaire, and more general tools like the Total Symptom Score can aid diagnosis, characterization, and monitoring of pain in patients with FD. These tools can be complemented by more objective and quantifiable sensory testing. In male and female patients of any age, pain related to FD can be an early indication to start disease-specific enzyme replacement therapy before potentially irreversible organ damage to the kidneys, heart, or brain occurs. Conclusion: To improve treatment outcomes, pain should be diagnosed early in unrecognized or newly identified FD patients. Treatment should include: (a) enzyme replacement therapy controlling the progression of underlying pathology; (b) adjunctive, symptomatic pain management with analgesics for chronic neuropathic and acute nociceptive, and inflammatory or mixed pain; and (c) lifestyle modifications. KW - Enzyme replacement therapy KW - Small fiber dysfunction KW - System involvement KW - Outcome survey KW - Fabry disease KW - Randomized controlled-trial KW - Chronic neuropathic pain KW - Agalsidase beta KW - Screening questionnaire KW - Dose reduction KW - Adult patients KW - Diagnosis KW - Pain KW - Peripheral nervous system Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-188127 VL - 22 IS - 7 ER - TY - JOUR A1 - Oder, Daniel A1 - Üceyler, Nurcan A1 - Liu, Dan A1 - Hu, Kai A1 - Petritsch, Bernhard A1 - Sommer, Claudia A1 - Ertl, Georg A1 - Wanner, Christoph A1 - Nordbeck, Peter T1 - Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y JF - BMJ Open N2 - Objectives: The severity of Fabry disease is dependent on the type of mutation in the α-galactosidase A (AgalA) encoding gene (GLA). This study focused on the impact of the GLA haplotype D313Y on long-term organ involvement and function. Setting and participants: In this monocentric study, all participants presenting with the D313Y haplotype between 2001 and 2015 were comprehensively clinically investigated at baseline and during a 4-year follow-up if available. Five females and one male were included. Primary and secondary outcome measures: Cardiac, nephrological, neurological, laboratory and quality of life data. Results: AgalA enzyme activity in leucocytes (0.3±0.9 nmol/min/mg protein (mean±SD)) and serum lyso-Gb3 (0.6±0.3 ng/mL at baseline) were in normal range in all patients. Cardiac morphology and function were normal (left-ventricular (LV) ejection fraction 66±8%; interventricular septum 7.7±1.4 mm; LV posterior wall 7.5±1.4 mm; normalised LV mass in MRI 52±9 g/m2; LV global longitudinal strain −21.6±1.9%) and there were no signs of myocardial fibrosis in cardiac MRI. Cardiospecific biomarkers were also in normal range. Renal function was not impaired (estimated glomerular filtration rate MDRD 103±15 mL/min; serum-creatinine 0.75±0.07 mg/dL; cystatin-c 0.71±0.12 mg/L). One female patient (also carrying a Factor V Leiden mutation) had a transitory ischaemic attack. One patient showed white matter lesions in brain MRI, but none had Fabry-associated pain attacks, pain crises, evoked pain or permanent pain. Health-related quality of life analysis revealed a reduction in individual well-being. At long-term follow-up after 4 years, no significant change was seen in any parameter. Conclusions: The results of the current study suggest that the D313Y genotype does not lead to severe organ manifestations as seen in genotypes known to be causal for classical FD." KW - inherited metabolic disorders KW - Anderson-Fabry Disease KW - D313Y genotype KW - Fabry cardiomyopathy KW - Fabry nephropathy KW - Fabry-associated pain Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-161210 VL - 6 ER - TY - JOUR A1 - Evdokimov, Dimitar A1 - Frank, Johanna A1 - Klitsch, Alexander A1 - Unterecker, Stefan A1 - Warrings, Bodo A1 - Serra, Jordi A1 - Papagianni, Aikaterini A1 - Saffer, Nadine A1 - Meyer zu Altenschildesche, Caren A1 - Kampik, Daniel A1 - Malik, Rayaz A. A1 - Sommer, Claudia A1 - Üceyler, Nurcan T1 - Reduction of skin innervation is associated with a severe fibromyalgia phenotype JF - Annals of Neurology N2 - Objective: To assess patterns and impact of small nerve fiber dysfunction and pathology in patients with fibromyalgia syndrome (FMS). Methods: One hundred seventeen women with FMS underwent neurological examination, questionnaire assessment, neurophysiology assessment, and small fiber tests: skin punch biopsy, corneal confocal microscopy, microneurography, quantitative sensory testing including C-tactile afferents, and pain-related evoked potentials. Data were compared with those of women with major depressive disorder and chronic widespread pain (MD-P) and healthy women. Results: Intraepidermal nerve fiber density (IENFD) was reduced at different biopsy sites in 63% of FMS patients (MDP: 10%, controls: 18%; p < 0.001 for each). We found 4 patterns of skin innervation in FMS: normal, distally reduced, proximally reduced, and both distally and proximally reduced (p < 0.01 for each compared to controls). Microneurography revealed initial activity-dependent acceleration of conduction velocity upon low frequencies of stimulation in 1A fibers, besides 1B fiber spontaneous activity and mechanical sensitization in FMS patients. FMS patients had elevated warm detection thresholds (p < 0.01), impaired C-tactile afferents (p < 0.05), and reduced amplitudes (p < 0.001) of pain-related evoked potentials compared to controls. Compared to FMS patients with normal skin innervation, those with generalized IENFD reduction had higher pain intensity and impairment due to pain, higher disease burden, more stabbing pain and paresthesias, and more anxiety (p < 0.05 for each). FMS patients with generalized IENFD reduction also had lower corneal nerve fiber density (p < 0.01) and length (p < 0.05). Interpretation: The extent of small fiber pathology is related to symptom severity in FMS. This knowledge may have implications for the diagnostic classification and treatment of patients with FMS. KW - fibromyalgia Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-206168 VL - 86 IS - 4 ER -